Mounjaro (tirzepatide)
/ Eli Lilly, Cipla
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
3510
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
January 28, 2026
Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis.
(PubMed, Cancers (Basel))
- "In the first analysis, adult patients with pre-existing CP were identified and stratified by use of a GLP-1 RA (semaglutide, dulaglutide, tirzepatide, exenatide, liraglutide, lixisenatide, and albiglutide). Propensity score matching (PSM) was conducted between GLP1-RA users and non-users, matching for age, sex, race, tobacco use, alcohol use, hypertension, hyperlipidemia, obesity, and pancreatic cysts...Given the elevated cancer risk in CP, these findings suggest a potential beneficial effect of GLP-1RA use in this high-risk population. Prospective studies will be important to further analyze and confirm this potential benefit."
Journal • Cardiovascular • Diabetes • Dyslipidemia • Genetic Disorders • Hypertension • Metabolic Disorders • Obesity • Oncology • Pancreatic Cancer • Pancreatitis • Solid Tumor • Type 2 Diabetes Mellitus
February 05, 2026
Preoperative Glucagon-like Peptide-1 Therapy in Bariatric Surgery Patients with Morbid Obesity (PreMO): Rationale and Study Design for a Randomized Controlled Trial.
(PubMed, J Surg Res)
- "Completion of this pilot RCT will provide data to support initiation of a multicenter RCT to determine therapeutic efficacy, and mechanisms of action, by which patients could benefit from preoperative treatment with tirzepatide."
Journal • Genetic Disorders • Inflammation • Metabolic Disorders • Obesity
February 05, 2026
Mounjaro: “Q4 2025 Mounjaro sales increased $3.9B
(Eli Lilly)
- Q4 2025 Results
Commercial • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity
February 05, 2026
A personalized, evidence-based approach to obesity therapy using clinical algorithms: semaglutide or tirzepatide
(PubMed, Probl Endokrinol (Mosk))
- "The discussion focused on the personalized approach of tirzepatide («Tirzetta®») and semaglutide («Velgia Eco®») in patients with excess body weight, obesity, and type 2 diabetes. Following the meeting, the objective was set to develop a consensus-based algorithm for prescribing these drugs to ensure their effective use in Russian clinical practice."
Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus
February 05, 2026
Mounjaro: Primary completion and completion of P3 SURMOUNT-MMO trial (NCT05556512) for obesity in Oct 2027
(Eli Lilly)
- Q4 2025 Results: Primary completion of P3 SYNERGY-Outcomes trial (NCT07165028) in adults with MASLD in Aug 2030; Completion of P3 SYNERGY-Outcomes trial in adults with MASLD in Aug 2032
Trial completion date • Trial primary completion date • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity
February 05, 2026
Mounjaro: Primary completion and completion of P3 SURMOUNT-MAINTAIN trial (NCT06047548) for obesity in May 2026
(Eli Lilly)
- Q4 2025 Results: Primary completion of P3 SURMOUNT-ADOLESCENTS trial (NCT06075667) for obesity in May 2026; Completion of P3 SURMOUNT-ADOLESCENTS trial for obesity in Jul 2029
Trial completion date • Trial primary completion date • Obesity
February 04, 2026
RFX6 maturity-onset diabetes of the young: clinical considerations and novel use of tirzepatide.
(PubMed, Endocrinol Diabetes Metab Case Rep)
- "Both required insulin during pregnancy and delivered healthy babies at 38 weeks...Tirzepatide may be a beneficial therapeutic option for managing patients with RFX6-MODY who have adequate β-cell function. Pregnancy management in patients with RFX6-MODY is similar to type 2 DM, although higher insulin doses may be required."
Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
January 30, 2026
A Case of Euglycemic Diabetic Ketoacidosis With Tirzepatide Use and Severe Calorie Restriction.
(PubMed, JCEM Case Rep)
- "While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and combined GLP-1/glucose-dependent insulinotropic polypeptide receptor agonists (GLP-1/GIP RAs), like tirzepatide, are effective for weight loss and diabetes management, their unsupervised use, especially alongside ketosis-inducing diets, may lead to serious risks such as EDKA. This report emphasizes the need for medical supervision in weight management, particularly when combining medications such as tirzepatide with dietary interventions, like IF and low-carbohydrate diets."
Journal • Diabetes • Genetic Disorders • Metabolic Disorders
January 29, 2026
CGM METRICS IN ADULTS WITH TYPE 1 DIABETES USING TIRZEPATIDE FOR >12 MONTHS
(ATTD 2026)
- No abstract available
Clinical • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus
January 29, 2026
THE RELATIONSHIP BETWEEN ADVERSE EVENTS AND PATIENT PROFILES IN TIRZEPATIDE AND SEMAGLUTIDE USERS WITH TYPE 1 DIABETES IN REAL-WORLD SETTINGS
(ATTD 2026)
- No abstract available
Adverse events • Clinical • Real-world • Real-world evidence • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus
January 27, 2026
A multimodal HPLC stability indicating approach for the estimation of Semaglutide and Tirzepatide in bulk, pharmaceutical dosage forms, and rat plasma: a six-edged sustainability appraisal.
(PubMed, BMC Chem)
- "The obtained linearity range for both TIR and SEM was 1-500 µg/mL with correlation coefficients > 0.9999. An in-depth six- edged sustainability assessment of the proposed method was conducted using greenness, whiteness, blueness and violet innovation metrics was performed using Analytical Greenness Metric (AGREE), Modified Green Analytical Procedure Index (MoGAPI), Analytical Eco-scale, Analytical Green Star Area (AGSA), Carbon Footprint Reduction Index (CaFRI), Whiteness using RGB algorithm, Blue Applicability Grade Index (BAGI), Click Analytical Chemistry Index (CACI), Violet Innovation Grade Index (VIGI) tools and Stability Toolkit for the Appraisal of Bio/Pharmaceuticals' Level of Endurance (STABLE)."
Journal • Preclinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
January 29, 2026
THE COMBINED EFFECT OF RT-CGM AND TIRZEPATIDE ON HBA1C IN PEOPLE WITH TYPE 2 DIABETES ON INTENSIVE INSULIN OR BASAL INSULIN THERAPIES
(ATTD 2026)
- No abstract available
Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
January 27, 2026
POSTER OF DISTINCTION: GLUCAGON-LIKE 1 RECEPTOR AGONIST USE WAS ASSOCIATED WITH IMPROVED OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A LARGE REAL-WORLD DATABASE STUDY
(CCCongress 2026)
- "Introduction: The utilization of glucagon-like peptide 1 receptor agonists (GLP-1RA) is rising for the treatment of obesity, with emerging data to suggest that they may also exert anti-inflammatory effects beyond weight loss...GLP-1RA exposure was defined as having a GLP-1RA (liraglutide, semaglutide, tirzepatide) ordered or administered at least twice... The use of GLP-1 receptor analogs was associated with improved IBD-specific outcomes in patients with UC and CD. Further study is needed to better define the true impact of GLP1RA on IBD-specific outcomes, ideally with more granular measures of disease activity."
Clinical • Real-world • Real-world evidence • Crohn's disease • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • Ulcerative Colitis
February 03, 2026
A Real-World Study on the Impact of Weight Loss on Treatment Efficacy in Overweight/Obese Patients With Plaque Psoriasis
(clinicaltrials.gov)
- P=N/A | N=70 | Not yet recruiting | Sponsor: Peking University Third Hospital
New trial • Real-world evidence • Dermatology • Immunology • Obesity • Psoriasis
January 30, 2026
Tirzepatide mitigates thoracic aortic aneurysm and dissection by alleviating the loss of the contractile phenotype in vascular smooth muscle cells and reducing vascular inflammation.
(PubMed, Vascul Pharmacol)
- "Our findings indicate that tirzepatide curbs the development of TAAD in mice. The underlying mechanism likely involves the suppression of the NLRP3 inflammasome priming, a consequent reduction in vascular inflammation, and the preservation of the contractile state of VSMC. These findings highlight its potential as a novel therapeutic strategy for TAAD."
Journal • Cardiovascular • Diabetes • Inflammation • Metabolic Disorders • Type 2 Diabetes Mellitus • CNN1 • IL1B • IL6 • NLRP3
January 29, 2026
INCIDENT DIABETIC EYE DISEASES AFTER TIRZEPATIDE TREATMENT FOR 1 YEAR IN PEOPLE WITH TYPE 1 DIABETES
(ATTD 2026)
- No abstract available
Diabetes • Diabetic Retinopathy • Metabolic Disorders • Ophthalmology • Retinal Disorders • Type 1 Diabetes Mellitus
January 29, 2026
Addressing patient concerns about the 'newness' and long-term safety of GLP-1 receptor agonists: A clinician's guide to counseling.
(PubMed, Am J Prev Cardiol)
- "Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes, obesity and cardiovascular health, yet some patients remain hesitant to start these therapies due to perceptions that they are "new" or unproven...A practical counseling checklist and sample patient-centric language are included to facilitate shared decision-making. In sum, clinicians can confidently reassure patients that GLP-1RAs are well-studied, mechanism-based therapies with millions of patient-years of experience supporting their safety and efficacy."
Journal • Cardiovascular • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Oncology • Type 2 Diabetes Mellitus
January 27, 2026
REPOSITIONING DUAL GLP-1/GIP RECEPTOR AGONISTS FOR THE TREATMENT OF COLITIS AND COLITIS-ASSOCIATED TUMORIGENESIS
(CCCongress 2026)
- "Treated mice exhibited improved weight stability independent of obesity, reflecting attenuation of inflammation and tumorigenesis rather than metabolic effects...Its dual receptor activity may synergize with existing therapies such as mesalamine or biologics, offering an advanced combination therapeutic approach to IBD management and cancer prevention. Future studies are warranted to define dosing strategies that dissociate metabolic from anti-inflammatory effects and to evaluate long-term outcomes in translational and clinical settings."
Colon Cancer • Colorectal Cancer • Crohn's disease • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammatory Bowel Disease • Metabolic Disorders • Obesity • Oncology • Solid Tumor • Type 2 Diabetes Mellitus • Ulcerative Colitis • CCND1 • CDKN1A • IL1B • IL6 • LCN2
February 03, 2026
Management of Obesity in Psoriasis Consultations.
(PubMed, Dermatol Ther (Heidelb))
- "Dermatologists should integrate obesity assessment and patient-centered interventions into psoriasis care. A structured, multidisciplinary approach could meaningfully enhance dermatological, metabolic, and cardiovascular outcomes in patients with psoriasis and obesity."
Journal • Cardiovascular • Dermatology • Genetic Disorders • Immunology • Inflammation • Obesity • Psoriasis
January 29, 2026
Incretin Analogues for Weight Reduction in Non-Diabetic Obese: A Review of Liraglutide, Semaglutide, and Tirzepatide Beyond Glycemic Control.
(PubMed, Rambam Maimonides Med J)
- "Liraglutide, semaglutide, and tirzepatide are the three incretin analogues approved for obesity in non-diabetic patients. This narrative review presents detailed comparisons of the three approved incretin analogues for obesity, their cost-effectiveness, and trends in the clinical setting."
Journal • Review • CNS Disorders • Gastrointestinal Disorder • Genetic Disorders • Metabolic Disorders • Obesity • Psychiatry • Type 2 Diabetes Mellitus
January 10, 2026
4022. Tirzepatide: A Dual GIP and GLP-1 Receptor Agonist
(ACC 2026)
- "Mounjaro® and Zepbound® and their delivery device bases are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. This program is sponsored by, and the speaker is presenting on behalf of, Lilly USA, LLC. Industry-Expert Theater presentations are not part of ACC.26, as planned by its Program Committee, and do not qualify for continuing medical education (CME), continuing nursing education (CNE) or continuing education (CE) credit."
January 29, 2026
TIRZEPATIDE IN TYPE 1 DIABETES: ONE-YEAR REAL-WORLD METABOLIC OUTCOMES FROM A LARGE UK CENTRE
(ATTD 2026)
- No abstract available
Clinical • Real-world • Real-world evidence • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus
February 04, 2026
Lilly last year became the first pharmaceutical company to hit a $1 trillion valuation, driven by the popularity of its weight-loss drug, Zepbound, in a rapidly expanding obesity market that is seeing newer avenues to bolster growth.
(Reuters)
- "Lilly expects to earn $33.50 to $35 per share on an adjusted basis this year, above analysts' average estimate of $33.23 per share. Sales are expected to be in the range of $80 billion to $83 billion, ahead of estimates of $77.62 billion....Sales of diabetes drug Mounjaro came in at $7.41 billion for the fourth quarter, compared with analysts' expectations of $6.63 billion. Zepbound clocked in sales of $4.3 billion for the quarter, above estimates of $3.41 billion."
Commercial • Sales • Obesity • Type 2 Diabetes Mellitus
January 10, 2026
REAL-WORLD COMPARATIVE OUTCOMES OF TIRZEPATIDE VERSUS SGLT2 INHIBITORS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND PERIPHERAL ARTERY DISEASE
(ACC 2026)
- "Abstract is embargoed at this time."
Clinical • Real-world • Real-world evidence • Cardiovascular • Diabetes • Metabolic Disorders • Peripheral Arterial Disease • Type 2 Diabetes Mellitus
January 28, 2026
Novo Nordisk spent nearly $500 million on U.S. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine months of 2025, more than double what Eli Lilly shelled out for its rival medicines, as the Danish drugmaker fought for market share....
(Yahoo Finance)
- "The data from advertising tracking firm MediaRadar, which has not been previously reported, shows Novo spent an estimated $316 million advertising its weight-loss drug Wegovy in the U.S. and $169 million on diabetes medication Ozempic from January through September last year. That's up 54% and 44%, respectively from the same period in 2024. Indianapolis-based market leader Eli Lilly spent about $131 million advertising obesity treatment Zepbound in the same period versus $2 million in 2024. It spent $83 million promoting diabetes medicine Mounjaro. Combined, Novo spent about $487 million and Lilly an estimated $214 million on U.S. ads for these drugs."
Commercial • Diabetes • Obesity
1 to 25
Of
3510
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141